LabGenius Therapeutics
LabGenius develops next-generation antibody and protein therapeutics to improve selectivity and tumor cell killing. The company applies a machine learning–driven evolution engine (EVA) that combines artificial intelligence, synthetic biology, and robotic automation to design, evolve, and screen antibody sequences. EVA is modality- and format-agnostic and supports LabGenius’s internal pipeline focused on selectivity-enhanced antibodies for solid tumors. The platform integrates ML models, high-throughput wet lab automation, and synthetic construct libraries to accelerate discovery and lead optimization. LabGenius advances a pipeline of therapeutic antibody candidates toward clinical development for oncology.
LabGenius Therapeutics
LabGenius develops next-generation antibody and protein therapeutics to improve selectivity and tumor cell killing. The company applies a machine learning–driven evolution engine (EVA) that combines artificial intelligence, synthetic biology, and robotic automation to design, evolve, and screen antibody sequences. EVA is modality- and format-agnostic and supports LabGenius’s internal pipeline focused on selectivity-enhanced antibodies for solid tumors. The platform integrates ML models, high-throughput wet lab automation, and synthetic construct libraries to accelerate discovery and lead optimization. LabGenius advances a pipeline of therapeutic antibody candidates toward clinical development for oncology.
TL;DR
Headquarters & founding: London; founded 2012
Core tech: EVA™ — ML-driven discovery engine combining machine learning, synthetic biology, and robotic automation
Focus: Discovery and optimisation of therapeutic antibodies for oncology (selectivity-enhanced antibodies, multispecific formats, T-cell engagers)
Recent financing: Series B £35M closed May 21, 2024 (led by M Ventures); company-reported total funding ~£58M
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Therapeutic antibody discovery and optimisation for oncology
Founded
2012
Industry
Biotechnology Research
Tech Stack
Funding Track Record
£35,000,000
Company reported this round brought total funding to ~£58M
Investor Signal
“Includes corporate VC and top-tier venture investors (M Ventures lead; participation from Octopus Ventures, LG, Atomico, Kindred Capital, Lux Capital, Obvious Ventures)”